(S)-3-(2-((4aR,6aS,7R,10aS,10bR)-3-(3-bromophenyl)-6a,10b-dimethyl-8-methylene-decahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)ethylidene)-4-hydroxy-dihydrofuran-2(3H)-one

ID: ALA379280

Chembl Id: CHEMBL379280

PubChem CID: 44411113

Max Phase: Preclinical

Molecular Formula: C27H33BrO5

Molecular Weight: 517.46

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C=C1CC[C@@H]2[C@]3(C)COC(c4cccc(Br)c4)O[C@@H]3CC[C@@]2(C)[C@@H]1C/C=C1/C(=O)OC[C@H]1O

Standard InChI:  InChI=1S/C27H33BrO5/c1-16-7-10-22-26(2,20(16)9-8-19-21(29)14-31-24(19)30)12-11-23-27(22,3)15-32-25(33-23)17-5-4-6-18(28)13-17/h4-6,8,13,20-23,25,29H,1,7,9-12,14-15H2,2-3H3/b19-8+/t20-,21-,22+,23-,25?,26+,27+/m1/s1

Standard InChI Key:  BDVGVXANMCQRAX-OPDNHIMUSA-N

Associated Targets(Human)

MGAM Tclin Maltase-glucoamylase (654 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GBA3 Tbio Beta-glucosidase cytosolic (63 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 517.46Molecular Weight (Monoisotopic): 516.1511AlogP: 5.49#Rotatable Bonds: 3
Polar Surface Area: 64.99Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.52CX Basic pKa: CX LogP: 5.60CX LogD: 5.60
Aromatic Rings: 1Heavy Atoms: 33QED Weighted: 0.33Np Likeness Score: 2.39

References

1. Dai GF, Xu HW, Wang JF, Liu FW, Liu HM..  (2006)  Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues.,  16  (10): [PMID:16504503] [10.1016/j.bmcl.2006.02.011]
2. Korzeniecki C, Priefer R..  (2021)  Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.,  211  [PMID:33228976] [10.1016/j.ejmech.2020.113006]

Source